{
  "id": 19449916,
  "title": "TD Cowen initiates Mentari stock with buy on migraine pipeline",
  "url": "https://urgent.news/2026/11/11/td-cowen-initiates-mentari-stock-with-buy-on-migraine-pipeline",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-11T05:02:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/td-cowen-initiates-mentari-stock-with-buy-on-migraine-pipeline-93CH-5017694"
  },
  "original_language": "en",
  "account": "TD Cowen has initiated coverage on Mentari Therapeutics (MTRI) with a buy rating, highlighting the company's migraine treatment pipeline focused on PACAP and CGRP pathways. Currently trading at $12.20, the stock has seen a 96% increase over the past six months, down from its 52-week high of $23.30. Migraine treatment options are limited, and TD Cowen believes Mentari's candidates could surpass the two-day efficacy benchmark of CGRP therapies by blocking both PACAP and CGRP pathways simultaneously. The migraine treatment market is projected to exceed $10 billion by 2030, with a market capitalization of $7.33 billion for Mentari. The company's lead asset, MT-001, is an anti-PACAP antibody in Phase I trials, with safety and pharmacokinetic data expected in mid-2027. MT-002, a PACAP and CGRP bispecific antibody, is projected to have a 77-day half-life. A second investigational new drug application is planned for Q1 2027, with Phase II trials beginning in early 2028. Approximately 50% of patients on CGRP therapies do not achieve at least a 50% reduction in monthly migraine days, highlighting the need for alternatives. Mentari's innovative approach has caught the attention of other analysts, including Stifel and Jefferies, who have also initiated coverage with a buy rating and a price target of $30.00.",
  "summary": null,
  "key_points": [
    "TD Cowen initiates coverage on Mentari Therapeutics with a buy rating",
    "Mentari's migraine pipeline targets PACAP and CGRP pathways",
    "Lead asset MT-001 in Phase I trials, Phase II starts early 2028"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}